Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 1.00 |
| ▸ | JUN | P05412 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | BCHE | P06276 | 1/20 | 0.66 |
| ▸ | GUSB | P08236 | 1/20 | 0.66 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.59 |
| ▸ | CDK4 | P11802 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160537 | 1.00 | NFKB1 (1.00) | NFKB1NFE2L2JUNCA1CA2 | |
| SCHEMBL29539991 | 1.00 | NFKB1 (1.00) | NFKB1NFE2L2JUNCA1CA2 | |
| SCHEMBL3329177 | 1.00 | NFKB1 (1.00) | NFKB1NFE2L2JUNCA1CA2 | |
| SCHEMBL11408172 | 0.98 | NFKB1 (0.96) | NFKB1NFE2L2JUNCA1CA2 | |
| SCHEMBL28838372 | 0.90 | NFKB1 (0.81) | NFKB1NFE2L2JUNCA1CA2 | |
| SCHEMBL28360814 | 0.90 | NFKB1 (0.81) | NFKB1NFE2L2JUNCA1CA2 | |
| SCHEMBL17068275 | 0.90 | NFKB1 (0.81) | NFKB1NFE2L2JUNCA1CA2 | |
| SCHEMBL27781268 | 0.90 | NFKB1 (0.81) | NFKB1NFE2L2JUNCA1CA2 | |
| SCHEMBL10448404 | 0.88 | NFKB1 (0.78) | NFKB1NFE2L2JUNCA1CA2 | |
| SCHEMBL10448403 | 0.88 | NFKB1 (0.78) | NFKB1NFE2L2JUNCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3471733-B1 | REAGENTS, COMPOSITIONS AND METHODS FOR IMPROVING VIABILITY AND FUNCTION OF CELLS, TISSUES AND ORGANS | TARGA BIOMEDICAL INC (CA) | 2024-08-07 | — | — | EP | claimed |
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| US-20230024103-A1 | REAGENTS, COMPOSITIONS AND METHODS FOR IMPROVING VIABILITY AND FUNCTION OF CELLS, TISSUES AND ORGANS | TARGA BIOMEDICAL (CA) | 2023-01-26 | — | — | US | claimed |
| US-11446265-B2 | Reagents, compositions and methods for improving viability and function of cells, tissues and organs | TARGA BIOMEDICAL (CA) | 2022-09-20 | — | — | US | claimed |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2021-03-11 | — | — | US | claimed |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2021-01-26 | — | — | US | claimed |
| US-9814731-B2 | Method for the induction of phase 2 related genes in a mammal comprising administering exemestane | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-14 | — | — | US | claimed |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2017-08-17 | — | — | US | claimed |
| US-20170196887-A1 | COMPOSITIONS COMPRISING EXEMESTANE AND NOVEL METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY | 2017-07-13 | — | — | US | claimed |
| US-9585894-B2 | Compositions comprising exemestane and novel methods of use | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-03-07 | — | — | US | claimed |
| WO-2016089648-A1 | BACH 1 INHIBITORS IN COMBINATION WITH NRF2 ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | VTV THERAPEUTICS LLC (US) | 2016-06-09 | — | — | WO | claimed |
| WO-2015009902-A1 | COMPOSITIONS COMPRISING EXEMESTANE AND NOVEL METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-01-22 | — | — | WO | claimed |
| US-20150025049-A1 | COMPOSITIONS COMPRISING EXEMESTANE AND NOVEL METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY | 2015-01-22 | — | — | US | claimed |
| US-12419849-B2 | Reagents, compositions and methods for improving viability and function of cells, tissues and organs | TARGA BIOMEDICAL INC. (CA) | 2025-09-23 | — | — | US | disclosed |
| US-20250073321-A1 | Modulation of Oxidative Stress and Amino Acid Metabolism for the Treatment or Prevention of Diseases and Disorders | UNIV NEW YORK (US) | 2025-03-06 | — | — | US | disclosed |
| US-12186377-B2 | Modulation of oxidative stress and amino acid metabolism for the treatment or prevention of diseases and disorders | NEW YORK UNIVERSITY (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2011014261-A1 | FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20070248705-A1 | Agents for Activating the Transcription Factor Nrf2 and Foods Having Such Function | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1813269-A1 | TRANSCRIPTIONAL FACTOR Nrf2 ACTIVATOR AND FOOD HAVING THE FUNCTION OF THE SAME IMPARTED THERETO | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-5077156-A | ANTISTATIC AND ELECTRICALLY CONDUCTIVE RELIEF IMAGES, PROCESSES FOR THE PRODUCTION THEREOF, COATING AGENTS AND RADIATION-SENSITIVE POLYMERS | CIBA-GEIGY CORPORATION (US) | 1991-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196887-A1 | COMPOSITIONS COMPRISING EXEMESTANE AND NOVEL METHODS OF USE | ESR2, NFE2L2, KEAP1 | NFKB1 268/4885NFE2L2 2/4885JUN 1714/4885 |
| US-20230024103-A1 | REAGENTS, COMPOSITIONS AND METHODS FOR IMPROVING VIABILITY AND FUNCTION OF CELLS, TISSUES AND ORGANS | NFE2L2, HSF1, HSPA9 | NFKB1 514/4885NFE2L2 1/4885JUN 566/4885 |
| US-12419849-B2 | Reagents, compositions and methods for improving viability and function of cells, tissues and organs | NFE2L2, HSF1, HSPA9 | NFKB1 514/4885NFE2L2 1/4885JUN 566/4885 |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | NFKB1 16/4885NFE2L2 3/4885JUN 313/4885 |
| US-11446265-B2 | Reagents, compositions and methods for improving viability and function of cells, tissues and organs | NFE2L2, HSF1, HSPA9 | NFKB1 514/4885NFE2L2 1/4885JUN 566/4885 |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | NFKB1 56/4885NFE2L2 3/4885JUN 324/4885 |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | NFKB1 43/4885NFE2L2 3/4885JUN 266/4885 |
| US-20150025049-A1 | COMPOSITIONS COMPRISING EXEMESTANE AND NOVEL METHODS OF USE | ESR2, NFE2L2, KEAP1 | NFKB1 268/4885NFE2L2 2/4885JUN 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.